Neurobiologia clinica

Condividi su

Gruppo guidato da Antonio Bertolotto

Neurobiologia clinica
Antonio Bertolotto

Antonio Bertolotto

Head physician, Neurologist, S. Luigi Gonzaga Hospital

Contacts:
Tel. + 39 011 9026697
Fax: +39 011 9026 397
mail: antonio.bertolotto@gmail.com

Curriculum
Born in Chiusa di Pesio on 12.2.1952. Italian.

Education/training 
1975-1977: Medical Intern. Division of Neurology, Department of Neuroscience, University of Turin. Mentor: Prof. D. Schiffer
1977: Doctor of Medicine e Surgery cum laude, University of Turin
1977-1981: Resident in Neurology, Division of Neurology, Department of Neuroscience, University of Turin, Turin. Mentor: Prof. D. Schiffer.

Work experience
1982 -1992 Neurological Clinic, University of Turin (Italy), vice-head
1992-2002 Neurological Clinic, University Hospital S. Luigi, Orbassano, vice-head
2002-2009 Multiple Sclerosis Regional Referral Centre (CRESM) & Clinical Neuro-Biology (CNB), University Hospital S. Luigi, Orbassano, Director
2009-2016 Neurological Unit 2 – CRESM, University Hospital S. Luigi, Orbassano, Director
2017-present Neurological Unit & CRESM (2200 MS patients) University Hospital S. Luigi, Orbassano, Director

Main activities
Daily clinical management of MS patients
Coordination of clinical, research, tutorial and diagnostic activities of CRESM
Reviewer for scientific journals; consultancy for pharmacological companies
Consultancy for MS Italian Society (AISM)
Fund-raising for Multiple Sclerosis research and treatment

Competences
Clinical Neurology focused on MS; Clinical trials management; CSF analysis, Anti-biopharmaceuticaa Abs
Research field Currently: Autologous Hematopoietic Stem Cell Transplantation in MS, Biopharmaceutical antibodies; Interferon beta Biological activity; Gene expression in pregnant MS patients; Nuclear Receptors; Anti-Aquaporin 4 and anti-MOG antibodies, MS clinical trials, SIMOA quantification of NFL and GFAP.

Field of research
Dr Bertolotto's professional interests include clinical studies on drugs immunogenicity, interferon-beta pharmacogenomics and pregnancy in multiple sclerosis and autoimmune diseases.

Currently:
Autologous Hematopoietic Stem Cell Transplantation in MS, Biopharmaceutical antibodies;
Interferon beta Biological activity;
Gene expression in pregnant MS patients;
Nuclear Receptors;
Anti-Aquaporin 4 and anti-MOG antibodies, MS clinical trials, SIMOA quantification of NFL and GFAP.

Membership in research centres:
Neuroscience Institute Cavalieri Ottolenghi (NICO, Turin); Neuroscience Institute Turin (NIT).

Professional organization
American Academy of Neurology (AAN); Italian Society of Neurology (SIN); Associazione Italiana Neuroimmunologia (AINI);Società dei Neurologi, Neurochirurghi e Neuroradiologi ospedalieri (SNO).

Administrative post
Member of the Scientific Committee of the Italian Multiple Sclerosis society (FISM/AISM).
Member of the "Therapeutics and Technology Assessment subcommittee of the American Academy of Neurology" regarding anti-IFN beta antibodies.
Member of the Steering Committee of the Europen NABINMS project [sponsored by the European Union under the Sixth Framework Programme (contract number 018926)]
Chairman of the Piedmont Regional Committee for Multiple Sclerosis (Assessorato alla Sanità).

National and International scientific activity
Grant reviewer for Associazione Italiana Sclerosi Multipla (AISM/FISM); and Istituto Superiore di Sanità.
Reviewer for Annals of Neurology, Neurology, Journal of Neuroimmunology, Multiple Sclerosis, European Neurology, Clinical Chemical Acta, Brain research, Experimental Cell Research, Journal of Interferon & Cytokine Research, Journal Neurology, Neurological Sciences, European Journal of Neurology, Therapeutic Advances in Neurological Disorders, The Pharmacogenomics journal.

Research Grants
Recipient of research grants from the Europen Community; Italian Ministry of Health; Piedmont Region; Associazione Italiana Sclerosi Multipla (AISM/FISM); San Paolo Foundation; Biogen Dompè; Merck-Serono; Sanofi-Aventis.

Scientific collaborations:

National:
Dr.ssa Aloisi Francesca; Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità (ISS), Roma.
Dr. Diego Franciotta; Laboratorio di Neuroimmunologia, IRCCS, Fondazione "Istituto Neurologico C. Mondino", Pavia.
Dr. Roberto Bergamaschi; Dipartimento di Scienze Neurologiche, IRCCS, Fondazione "Istituto Neurologico C. Mondino", Pavia.
Prof. Paolo Gallo; Centro Sclerosi Multipla, Dipartimento di Neuroscienze, I Clinica neurologica, Ospedale universitario di Padova, Padova.
Prof. Francesco Lolli; Prof. Luca Massacesi; Prof.ssa Maria Pia Amato; Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, Firenze.
Dr. Renato Mantegazza; Dr.ssa Graziella Filippini; U.O. Immunologia e Patologia Muscolare Neurologia IV, Istituto Nazionale Neurologico "Carlo Besta" (INNCB), Milano.
Prof. Giancarlo Comi; Divisione di Neurologia e Servizio di Neurofisiologia, Ospedale San Raffaele, Milano.
Dr. Gianvito Martino; Dr. Roberto Furlan; Unità di Neuroimmunologia, Dipartimento di Neuroscienze DIBIT2, Ospedale S. Raffaele, Milano.
Dr. Massimo Filippi; Unità di Neuroimaging Research (NRU), Ospedale S. Raffaele, Milano.
Prof. Marco Salvetti; Centro neurologico terapie sperimentali (Centers), Dipartimento di Scienze Neurologiche, II Facoltà di Medicina e Chirurgia, Università La Sapienza, Roma.
Prof.ssa Maria Trojano; Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Bari, Policlinico, Bari.
Prof Gianluigi Mancardi; Prof. Antonio Uccelli; Dipartimento di Neuroscienze, Oftalmologia e Genetica, Università degli studi di Genova, Genova.
Dr. Angelo Grezzi; Dr. Mauro Zaffarono; Centro Sclerosi Multipla, Azienda Ospedaliera S. Antonio Abate, Gallarate (VA).
Prof. Francesco Patti; Centro Sclerosi Multipla, Azienda Ospedaliero-Universitaria "G. Rodolico", Università degli Studi di Catania, Catania.
Prof. Roberto Mutani; Dr.ssa Paola Cavalla; Dipartimento di Neuroscienze, I facoltà di Medicina e Chirurgia, Università degli Studi di Torino, Ospedale Giovanni Battista, Torino.
Prof. Raffaele Calogero; Unità di Bioinformatica e genomica, Dipartimento di Scienze Cliniche e Biologiche, II facoltà di Medicina e chirurgia, Università degli Studi di Torino, AOU S. Luigi Gonzaga, Orbassano (TO).
Prof. Giuseppe Saglio; Divisione di Medicina interna ed Ematologia, Dipartimento di Scienze Cliniche e Biologiche, II facoltà di Medicina e chirurgia, Università degli Studi di Torino, AOU S. Luigi Gonzaga, Orbassano (TO).

International:
Prof. Ludwig Kappos, Prof.ssa Raija Lindberg Department of Research and Neurology, University Hospital Basel (Basel, Switzerland).
Prof. Chris Polman; Dr. Joep Killestein; Dr.ssa Laura van der Voort; Department of Neurology, VU Medical Centre, University of Amsterdam (Amsterdam, The Netherlands)
Dr. C. Teunissen, Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
Prof. Gavin Giovannoni; Institute of Cell and Molecular Science, Queen Mary University London, Department of Neurology, Barts and The London NHS Trust, The Royal London Hospital (London, UK).
Prof. Florian Deisenhammer; Neuroimmunology Laboratory, Innsbruck Medical University (Innsbruck, Austria)
Prof. Per Soelberg Sørensen, Danish Multiple Sclerosis Research Center, Department of Neurology, Copenhagen University Hospital (Copenhagen, Denmark).
Prof. Jan Hillert; Prof. Anna Fogdell-Hahn; Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Karolinska University Hospital Huddinge (Stockholm, Sweden)
Prof. Huub Schellekens; Central Laboratory Animal Institute, Department of Pharmaceutical Sciences, Department of Innovation Studies, Utrecht University (Utrecht, The Netherlands)
Dr. Arno Kromminga; Immunology - Clinical Pathology - Molecular Medicine, IPM BIOTECH GmbH (Hamburg, Germany).
Prof. Wim Jiskoot; Dr.ssa Miranda van Beers; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University (Utrecht, The Netherlands)
Prof. Joel Oger; Department of Neurology, UBC Hospital, University of British Columbia (Vancouver, Canada)
Prof. Klaus Bendtzen; BioMonitor A/S and CytoMab ApS, Symbion Science Park (Copenhagen, Denmark)
Prof. Andrew Pachner; Department of Neurology and Neurosciences, New Jersey Medical School (NJMS), University of Medicine and dentistry of New Jersey (UMDNJ) (Newark, NJ, USA)?Prof. Eva Havrdová; Dr.ssa Dana Horáková; MS Center, Department of Neurology, Charles University, General Teaching Hospital (Prague, Czech Republic)
Dr.ssa Eva Meluzínová; Dr.ssa Jana Libertinová; Neurologická klinika, FN Motol (Prague, Czech Republic).
Prof. Bernhard Hemmer; Department of Neurology, Klinikum Rechts der Isar, Technische Universitaet Muenchen (Muenchen, Germany).

Publications:

>  Publicationslist.org 

>  PubMed.gov

News

Sclerosi Multipla: lo spegnimento del gene TNFAIP3 indica possibili bersagli terapeutici

La mancanza del gene TNFAIP3 nelle cellule mieloidi porta a una alterata produzione delle cellule del sistema immunitario responsabili della difesa dell’organismo e dell’insorgenza di malattie autoimmuni. È quanto dimostra lo studio pubblicato su International Journal of Molecular Science dalle ricercatrici del laboratorio di Neurobiologia Clinica diretto dal Dr. Bertolotto.

29 Aprile 2020